In this section
These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.
Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay
This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans. For more, please see the associated New and Views.
See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.
The mechanism of resistance to favipiravir in influenza. PNAS (2018).
, , , , ,
Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay
Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.
@article{Singanayagam:2017:10.1016/S1473-3099(17)30360-2,
author = {Singanayagam, A and Zambon, M and Lalvani, A and Barclay, W},
doi = {10.1016/S1473-3099(17)30360-2},
journal = {Lancet Infectious Diseases},
pages = {e25--e32},
title = {Urgent challenges in implementing live attenuated influenza vaccine.},
url = {http://dx.doi.org/10.1016/S1473-3099(17)30360-2},
volume = {18},
year = {2017}
}
TY - JOUR
AB - Conflicting reports have emerged about the effectiveness of the live attenuated influenza vaccine. The live attenuated influenza vaccine appears to protect particularly poorly against currently circulating H1N1 viruses that are derived from the 2009 pandemic H1N1 viruses. During the 2015-16 influenza season, when pandemic H1N1 was the predominant virus, studies from the USA reported a complete lack of effectiveness of the live vaccine in children. This finding led to a crucial decision in the USA to recommend that the live vaccine not be used in 2016-17 and to switch to the inactivated influenza vaccine. Other countries, including the UK, Canada, and Finland, however, have continued to recommend the use of the live vaccine. This policy divergence and uncertainty has far reaching implications for the entire global community, given the importance of the production capabilities of the live attenuated influenza vaccine for pandemic preparedness. In this Personal View, we discuss possible explanations for the observed reduced effectiveness of the live attenuated influenza vaccine and highlight the underpinning scientific questions. Further research to understand the reasons for these observations is essential to enable informed public health policy and commercial decisions about vaccine production and development in coming years.
AU - Singanayagam,A
AU - Zambon,M
AU - Lalvani,A
AU - Barclay,W
DO - 10.1016/S1473-3099(17)30360-2
EP - 32
PY - 2017///
SN - 1473-3099
SP - 25
TI - Urgent challenges in implementing live attenuated influenza vaccine.
T2 - Lancet Infectious Diseases
UR - http://dx.doi.org/10.1016/S1473-3099(17)30360-2
UR - http://hdl.handle.net/10044/1/51902
VL - 18
ER -
For any enquiries related to this group, please contact:
Professor Wendy Barclay
Chair in Influenza Virology
+44 (020) 7594 5035
w.barclay@imperial.ac.uk